Rayno Life Science Portfolio: Regeneron(REGN)up 14% on Eye Drug Phase 3 Results
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every month.Regeneron and its...
Rayno Life Science Portfolio:Exelixis (EXEL) and Neogen (NEOG) Soar
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with castration-resistant prostate cancer (CRPC) achieving either partial or complete remission in 19/20 prostate...
Rayno SnowBlog: LaNina Advisory-Nat Gas Up on Cold Weather- Update
11/23/10 Nat Gas is approaching its mid-Sep highs as cold weather is forecasted to continue for the next 10-14 days. Today's high is $4.29 up from lows around $3.70 on Oct 25. The Jan.'11 Futures Contracts is at $4.39 Quotes & Charts with Indicators - Stocks Options Futures Forex - Traders...
Microfluidics (MFLU.OB) Revenues Down 9% but Value Play Intact
Microfluidics reported revenues of $4.1M for Q3 2010 ended Sep 30 a decrease of 9% or $500k compared to the same period of 2009. Excluding revenues of $1.3M attributed to machine production of the 2009 H1N1 Flu pandemic, revenues grew 29%.Unit sales increased to 144 units compared to 127 units...
Rayno Life Science Portfolio Update: BLUD,ILMN, NEOG,SQNM
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is a leader in automated blood transfusion systems but still faces...